Having trouble accessing articles? Reset your cache.

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give Regeneron the most advanced program in this rare bone disease.

Ipsen Group (Euronext:IPN) said on Friday that it would pause dosing in patients in Phase III trial of palovarotene to

Read the full 649 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers